NIS - libdoc.who.int - World Health Organization

Radix Glycyrrhizae
46. Rask-Madsen J et al. Effect of carbenoxolone on gastric prostaglandin E2
levels in patients with peptic ulcer disease following vagal and pentagastrin
stimulation. European journal of clinical investigation, 1983, 13:875–884.
47. Kassir ZA. Endoscopic controlled trial of four drug regimens in the treatment
of chronic duodenal ulceration. Irish medical journal, 1985, 78:153–
156.
48. Molhuysen JA et al. A liquorice extract with deoxycortone-like action. Lancet,
1950, ii:381–386.
49. Groen J et al. Extract of licorice for the treatment of Addison’s disease. New
England journal of medicine, 1951, 244:471–475.
50. Card WI et al. Effects of liquorice and its derivatives on salt and water metabolism.
Lancet, 1953, i:663–667.
51. Groen J et al. Effect of glycyrrhizinic acid on the electrolyte metabolism in
Addison’s disease. Journal of clinical investigation, 1952, 31:87–91.
52. Doll R. Treatment of gastric ulcer with carbenoxolone: antagonistic effect of
spironolactone. Gut, 1968, 9:42–45.
53. Sakai Y et al. Effects of medicinal plant extracts from Chinese herbal medicines
on the mutagenic activity of benzo[a]pyrene. Mutation research, 1988,
206:327–334.
54. Lee HK et al. Effect of bacterial growth-inhibiting ingredients on the Ames
mutagenicity of medicinal herbs. Mutation research, 1987, 192:99–104.
55. Yamamoto H, Mizutani T, Nomura H. Studies on the mutagenicity of crude
drug extracts. I. Yakugaku zasshi, 1982, 102:596–601.
56. Leslie GB, Salmon G. Repeated dose toxicity studies and reproductive studies
on nine Bio-Strath herbal remedies. Swiss medicine, 1979, 1:1–3.
57. Epistein MT et al. Effects of eating liquorice on the renin-angiotensin aldosterone
axis in normal subjects. British medical journal, 1977, 1:488–490.
58. Stewart PM et al. Mineralocorticoid activity of liquorice: 11-β hydroxysteroid
dehydrogenase deficiency comes of age. Lancet, 1987, ii:821–824.
59. Caradonna P et al. Acute myopathy associated with chronic licorice ingestion:
Reversible loss of myoadenylate deaminase activity. Ultrastructural
pathology, 1992, 16:529–535.
173